HN30
Research HN30 on Bullrun: market cap EUR 2.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHN30
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 2.36M
- Financial periodQ1 2026
- RevenueCAD 134.55K
- Net income-CAD 326.14K
- Free cash flow-CAD 74.07K
- Gross margin46.0%
Valuation Snapshot
latest market cap is EUR 2.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 1.39M | -CAD 717.22K | n/a | n/a | CAD 1.60M | CAD 245.36K | CAD 1.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 2.36M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About HN30
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HN30's market cap?
HN30's market capitalization is EUR 2.36M.
What does HN30 do?
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap.